Approach resulted in transfusion independence and durable anemia response
Study matches momelotinib against danazol
Momelotinib, a new JAK inhibitor, inches closer to market approval
Dose-finding trial adds to evidence of efficacy
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Interim results of phase 2 trial are promising
Second (or third) time’s a charm in reducing splenomegaly and other symptoms
Final results of PERSIST-2 confirm benefit; PAC203 enrolling